JP2022545568A5 - - Google Patents

Info

Publication number
JP2022545568A5
JP2022545568A5 JP2022521405A JP2022521405A JP2022545568A5 JP 2022545568 A5 JP2022545568 A5 JP 2022545568A5 JP 2022521405 A JP2022521405 A JP 2022521405A JP 2022521405 A JP2022521405 A JP 2022521405A JP 2022545568 A5 JP2022545568 A5 JP 2022545568A5
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical composition
vitiligo
week
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022521405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545568A (ja
JP7532511B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036985 external-priority patent/WO2020252012A1/en
Publication of JP2022545568A publication Critical patent/JP2022545568A/ja
Publication of JP2022545568A5 publication Critical patent/JP2022545568A5/ja
Priority to JP2024075642A priority Critical patent/JP2024105436A/ja
Application granted granted Critical
Publication of JP7532511B2 publication Critical patent/JP7532511B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521405A 2019-06-10 2020-06-10 Ｊａｋ阻害剤による尋常性白斑の局所治療 Active JP7532511B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024075642A JP2024105436A (ja) 2019-06-10 2024-05-08 Ｊａｋ阻害剤による尋常性白斑の局所治療

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US201962859495P 2019-06-10 2019-06-10
US201962859506P 2019-06-10 2019-06-10
US201962859584P 2019-06-10 2019-06-10
US201962859601P 2019-06-10 2019-06-10
US201962859532P 2019-06-10 2019-06-10
US62/859,532 2019-06-10
US62/859,584 2019-06-10
US62/859,601 2019-06-10
US62/859,506 2019-06-10
US62/859,495 2019-06-10
US201962894564P 2019-08-30 2019-08-30
US201962894581P 2019-08-30 2019-08-30
US201962894496P 2019-08-30 2019-08-30
US201962894541P 2019-08-30 2019-08-30
US201962894514P 2019-08-30 2019-08-30
US62/894,496 2019-08-30
US62/894,581 2019-08-30
US62/894,541 2019-08-30
US62/894,564 2019-08-30
US62/894,514 2019-08-30
US201962911845P 2019-10-07 2019-10-07
US62/911,845 2019-10-07
US202062967879P 2020-01-30 2020-01-30
US62/967,879 2020-01-30
PCT/US2020/036985 WO2020252012A1 (en) 2019-06-10 2020-06-10 Topical treatment of vitiligo by a jak inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024075642A Division JP2024105436A (ja) 2019-06-10 2024-05-08 Ｊａｋ阻害剤による尋常性白斑の局所治療

Publications (3)

Publication Number Publication Date
JP2022545568A JP2022545568A (ja) 2022-10-27
JP2022545568A5 true JP2022545568A5 (cg-RX-API-DMAC10.html) 2023-06-20
JP7532511B2 JP7532511B2 (ja) 2024-08-13

Family

ID=73651112

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521405A Active JP7532511B2 (ja) 2019-06-10 2020-06-10 Ｊａｋ阻害剤による尋常性白斑の局所治療
JP2024075642A Pending JP2024105436A (ja) 2019-06-10 2024-05-08 Ｊａｋ阻害剤による尋常性白斑の局所治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024075642A Pending JP2024105436A (ja) 2019-06-10 2024-05-08 Ｊａｋ阻害剤による尋常性白斑の局所治療

Country Status (10)

Country Link
US (4) US11602536B2 (cg-RX-API-DMAC10.html)
EP (1) EP3982971A4 (cg-RX-API-DMAC10.html)
JP (2) JP7532511B2 (cg-RX-API-DMAC10.html)
AU (2) AU2020290995B2 (cg-RX-API-DMAC10.html)
CA (1) CA3150975A1 (cg-RX-API-DMAC10.html)
IL (1) IL290637A (cg-RX-API-DMAC10.html)
MA (1) MA56215A (cg-RX-API-DMAC10.html)
TW (1) TW202112377A (cg-RX-API-DMAC10.html)
UA (1) UA130944C2 (cg-RX-API-DMAC10.html)
WO (1) WO2020252012A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008850A2 (pt) 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
JP7591500B2 (ja) 2018-08-10 2024-11-28 アクラリス セラピューティクス，インコーポレイテッド ピロロピリミジンｉｔｋ阻害剤
US11602536B2 (en) * 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor
US20230364095A1 (en) * 2020-09-16 2023-11-16 Incyte Corporation Topical treatment of vitiligo
CN117279915A (zh) * 2021-02-18 2023-12-22 阿克拉瑞斯治疗股份有限公司 Jak1/3抑制剂的局部制剂及其用于特异性皮炎和其他皮肤病况的治疗的方法
JP2024509383A (ja) * 2021-02-18 2024-03-01 アクラリス セラピューティクス，インコーポレイテッド アトピー性皮膚炎及びその他の皮膚状態の治療のためのｊａｋ１／３阻害剤の局所製剤及びその使用方法
EP4389114A4 (en) * 2021-08-19 2025-09-03 Zhuhai United Laboratories Co Ltd LOCAL TOPICAL FORMULATION CONTAINING A JAK INHIBITOR OR A SALT THEREOF OR A CRYSTALLINE FORM THEREOF, PREPARATION METHOD THEREOF AND CORRESPONDING APPLICATION
CN115869321A (zh) 2021-09-28 2023-03-31 杭州中美华东制药有限公司 一种芦可替尼组合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP2006502183A (ja) 2002-09-20 2006-01-19 アルコン，インコーポレイテッド ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
JP2019534304A (ja) 2016-11-10 2019-11-28 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性疾患の治療のための化合物及びその医薬組成物
US11957931B2 (en) 2017-04-26 2024-04-16 Yale University Compositions and methods for treating vitiligo
US20190060311A1 (en) 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
CN111374639A (zh) 2018-12-28 2020-07-07 陈柏龄 败血症的菌种预测系统与方法
US20210030672A1 (en) 2019-06-10 2021-02-04 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
US11602536B2 (en) * 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor

Similar Documents

Publication Publication Date Title
Mawdsley Treatment of Parkinsonism with Laevo-dopa
US9782438B2 (en) Method of promoting hair growth by administration of BFGF
US12233067B2 (en) Topical treatment of vitiligo by a JAK inhibitor
JPH0653681B2 (ja) 体重の選択的減量のための組成物
KR20190084028A (ko) 두개 신경의 약리학적 피부 활성화에 의한 신경변성 질환과 관련된 증상의 치료
Fischer et al. Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat
Ross et al. Effects of topically applied isoproterenol on aqueous dynamics in man
Brown et al. Systemic complications associated with retinal cryoablation for retinopathy of prematurity
WINTON Anesthesia for dermatologic surgery
US4608365A (en) Treatment of neurologic functions
US20210030672A1 (en) Topical treatment of vitiligo by a jak inhibitor
US20240189382A1 (en) Formula for inhibiting aging regeneration repair
WO2001000196A2 (en) Mirtazapine for weight gain in wasting diseases
West et al. Sudden hypotension associated with midazolam and sufentanil
HUP0100599A2 (hu) Lokális anesztetikumok új alkalmazása vaszkuláris fejfájások ellen
JP2023542137A5 (cg-RX-API-DMAC10.html)
US12390426B1 (en) Use of adamantane compositions and methods of reducing fibrotic tissue
Luduena et al. 2-phenyl-4-thiazolidone derivatives as local anesthetics
RU2638271C1 (ru) Способ коррекции и профилактики возрастных изменений кожи лица
Winkelman et al. Prostigmin in the Treatment of Myasthenia Gravis and Muscular Dystrophy: Results Obtained with Divided Doses
Akinyemi et al. Evaluation of the perioperative analgesic effects of caudal block for herniotomy in children at the University College Hospital Ibadan, Nigeria
JP2011506413A (ja) 瘢痕化阻害の方法
US20230293431A1 (en) Topical treatment of vitiligo by a jak inhibitor
WO1995023580A1 (en) Preventive and remedy for secondary depilation
JPH02501570A (ja) 脱毛症を治療するためのニコランジルの使用